PE20160239A1 - SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN - Google Patents

SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Info

Publication number
PE20160239A1
PE20160239A1 PE2016000043A PE2016000043A PE20160239A1 PE 20160239 A1 PE20160239 A1 PE 20160239A1 PE 2016000043 A PE2016000043 A PE 2016000043A PE 2016000043 A PE2016000043 A PE 2016000043A PE 20160239 A1 PE20160239 A1 PE 20160239A1
Authority
PE
Peru
Prior art keywords
paracetamol
celecoxib
inflammatory pain
treatment
synergistic combination
Prior art date
Application number
PE2016000043A
Other languages
Spanish (es)
Inventor
Medellin Jorge Fernando Cantu
Original Assignee
More Pharma Corp S De R L De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corp S De R L De C V filed Critical More Pharma Corp S De R L De C V
Publication of PE20160239A1 publication Critical patent/PE20160239A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Se refiere a una combinacion de paracetamol y celecoxib que en cantidades especificas generan una potenciacion analgesica contra el dolor de tipo inflamatorio. Especificamente, la invencion se refiere a una combinacion sinergistica de entre 375 a 500 mg de paracetamol y de entre 50 a 75 mg de celecoxib util para el tratamiento de dolor inflamatorio en animales y seres humanos, asi como el uso de dichos principios activos en las cantidades indicadas en la preparacion de combinaciones farmaceuticas sinergistas.It refers to a combination of paracetamol and celecoxib that in specific amounts generate an analgesic potentiation against inflammatory pain. Specifically, the invention relates to a synergistic combination of between 375 to 500 mg of paracetamol and between 50 to 75 mg of celecoxib useful for the treatment of inflammatory pain in animals and humans, as well as the use of said active principles in the amounts indicated in the preparation of synergistic pharmaceutical combinations.

PE2016000043A 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN PE20160239A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (en) 2013-07-11 2013-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain

Publications (1)

Publication Number Publication Date
PE20160239A1 true PE20160239A1 (en) 2016-05-13

Family

ID=52279400

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016002763A PE20170305A1 (en) 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN
PE2016000043A PE20160239A1 (en) 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016002763A PE20170305A1 (en) 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Country Status (8)

Country Link
CL (1) CL2015003211A1 (en)
CR (1) CR20160021A (en)
CU (1) CU24440B1 (en)
DO (1) DOP2016000008A (en)
EC (1) ECSP16005679A (en)
MX (1) MX366118B (en)
PE (2) PE20170305A1 (en)
WO (2) WO2015004505A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418533C (en) * 2002-02-19 2008-09-17 阿德科克因格拉姆有限公司 Pharmaceutical combinations of cox-2 inhibitors and opiates
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Also Published As

Publication number Publication date
PE20170305A1 (en) 2017-04-21
WO2015004505A1 (en) 2015-01-15
CL2015003211A1 (en) 2016-04-29
WO2015004634A3 (en) 2015-04-09
WO2015004634A2 (en) 2015-01-15
MX2015013911A (en) 2015-12-08
ECSP16005679A (en) 2017-08-31
CU24440B1 (en) 2019-09-04
CR20160021A (en) 2016-04-08
MX366118B (en) 2019-06-27
CU20160002A7 (en) 2016-06-29
DOP2016000008A (en) 2016-03-15

Similar Documents

Publication Publication Date Title
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
CL2014002087A1 (en) Chewable veterinary composition comprising as active agent an isoxazoline derivative compound; and its use for the treatment and / or prevention of an infestation and / or infection by parasites in an animal.
CL2015002677A1 (en) Compositions comprising selenium and their use for the treatment and prevention of diseases or conditions associated with mitochondrial dysfunction.
CL2015002941A1 (en) Therapeutic uses of empaglifozin
CU20150163A7 (en) DERIVATIVES OF 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO (3,4-c) PIRAZOL-6-ONA ACTIVE AS BET INHIBITORS
PE20180399A1 (en) TRANSDERMAL COMPOSITIONS OF IBUPROFEN AND METHODS OF USE OF THE SAME
PE20150631A1 (en) CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
CL2015002736A1 (en) Pharmaceutical composition of s-ketamine hydrochloride.
ECSP11011459A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
GT201700138A (en) PIRAZOLPIRIDINAMINAS
CL2015002433A1 (en) Imidazopyridazines substituted
CL2019001996A1 (en) Therapeutic uses of an insect powder.
DOP2012000279A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
GT201200304A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
BR112015029894A2 (en) solid pharmaceutical dosage form
CL2017000845A1 (en) Lysine Gingipain Inhibitors
DOP2016000007A (en) SUBSTITUTED PIRAZOLPIRIDINS
CO2018012180A2 (en) Treatment methods for cholestatic and fibrotic diseases
CR20140293A (en) PREPARATIONS THAT INCLUDE AMODFO EMODEPSIDO
BR112014031706A8 (en) Oral pharmaceutical compositions, and oral pharmaceutical composition comprising itraconazole
CL2015001225A1 (en) Therapeutic agent for keratoconjunctive disorders.
CL2010001594A1 (en) Use of nifurtimox to prepare a medicine useful in the treatment of diseases caused by trichomonadide.
CL2016001130A1 (en) Solid triglyceride compositions and uses of these
PE20160239A1 (en) SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Legal Events

Date Code Title Description
FA Abandonment or withdrawal